INmune Bio, Inc. (INMB)

Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.

The chart shows the growth of an initial investment of $10,000 in INmune Bio, Inc., comparing it to the performance of the S&P 500 index or another benchmark. All prices have been adjusted for splits and dividends.

INmune Bio, Inc. (INMB) has returned -27.56% so far this year and -85.53% over the past 12 months.

Based on dividend-adjusted daily data since Feb 4, 2019, INMB's average daily return is +0.06%, while the average monthly return is +1.03%. At this rate, your investment would double in approximately 5.6 years.

Historically, 36% of months were positive and 64% were negative. The best month was Jul 2020 with a return of +121.3%, while the worst month was Jun 2025 at -68.7%. The longest winning streak lasted 4 consecutive months, and the longest losing streak was 9 months.

On a daily basis, INMB closed higher 47% of trading days. The best single day was Jul 14, 2020 with a return of +78.0%, while the worst single day was Jun 30, 2025 at -56.7%.

INmune Bio, Inc. has an annualized alpha of -0.30%, beta of 1.14, and R² of 0.06 versus S&P 500 Index. Calculated based on daily prices since February 05, 2019.

• This stock participated in 179.98% of S&P 500 Index downside but only 47.30% of its upside — more exposed to losses than it benefited from rallies.
• R² of 0.06 means this stock moves largely independently of S&P 500 Index — capture ratios reflect limited market correlation rather than active downside protection. Consider using a more representative benchmark.

INMB ranks 7 for risk / return — in the bottom 7% of stocks on our site. This means you're taking on significantly more risk than the returns justify. Consider whether the potential upside is worth the volatility, or explore alternatives with better risk / return profiles.

The table below present risk-adjusted performance metrics for INmune Bio, Inc. (INMB) and compare them to a chosen benchmark (S&P 500 Index).

The Drawdowns chart displays portfolio losses from any high point along the way. Drawdowns are calculated considering price movements and all distributions paid, if any.

The table below displays the maximum drawdowns of the INmune Bio, Inc.. A maximum drawdown is a measure of risk, indicating the largest reduction in portfolio value due to a series of losing trades.

The maximum drawdown for the INmune Bio, Inc. was 95.98%, occurring on Mar 27, 2026. The portfolio has not yet recovered.

The current INmune Bio, Inc. drawdown is 95.94%.

The chart below shows the rolling one-month volatility.

The chart below illustrates the trends in the financial health of INmune Bio, Inc. over time, highlighting three key metrics: Total Revenue, Earnings Before Interest and Taxes (EBIT), and Net Income.

The Valuation section provides an overview of how INmune Bio, Inc. is priced in the market compared to other companies in the Biotechnology industry. It includes key financial ratios that help investors assess whether the stock is undervalued or overvalued.